Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04500548
Title	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Recruitment	Withdrawn
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	neuroblastoma lymphoma Advanced Solid Tumor central nervous system cancer
Therapies	Nivolumab Ipilimumab + Nivolumab
Age Groups:	adult \| child
Covered Countries	USA \| CAN